{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:17:16Z","timestamp":1784945836470,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40266-017-0510-6","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T06:24:03Z","timestamp":1516343043000},"page":"27-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Brain Over Bladder: A Systematic Review of Dual Cholinesterase Inhibitor and Urinary Anticholinergic Use"],"prefix":"10.1007","volume":"35","author":[{"given":"Laura K.","family":"Triantafylidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna S.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily P.","family":"Peron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Roefaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"issue":"7","key":"510_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40266-015-0281-x","volume":"32","author":"S Orme","year":"2015","unstructured":"Orme S, Morris V, Gibson W, Wagg A. Managing urinary incontinence in patients with dementia: pharmacologic treatment options and considerations. Drugs Aging. 2015;32(7):559\u201367.","journal-title":"Drugs Aging"},{"key":"510_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/nau.22928","volume":"36","author":"MA Averbeck","year":"2017","unstructured":"Averbeck MA, Ataweel W, Manu-Marin A, Madersbacher H. Management of LUTS in patients with dementia and associated disorders. Neurol Urodyn. 2017;36:245\u201352.","journal-title":"Neurol Urodyn"},{"issue":"5","key":"510_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1532-5415.2007.01143.x","volume":"55","author":"JM Star","year":"2007","unstructured":"Star JM. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer\u2019s disease. J Am Geriatr Soc. 2007;55(5):800\u20131.","journal-title":"J Am Geriatr Soc"},{"key":"510_CR4","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0140-6736(00)02588-5","volume":"356","author":"M Hashimoto","year":"2000","unstructured":"Hashimoto M, Imamura T, Tanimukai S, Kazui H, Mori E. Urinary incontinence: an unrecognized adverse effect with donepezil. Lancet. 2000;356:568.","journal-title":"Lancet."},{"issue":"6","key":"510_CR5","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1046\/j.1532-5415.2002.50281.x","volume":"50","author":"KR Edwards","year":"2002","unstructured":"Edwards KR, O\u2019Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc. 2002;50(6):1165\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"510_CR6","unstructured":"Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions\u00a0Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. \n                    www.handbook.cochrane.org\n                    \n                  . Accessed 10 Jan 2018."},{"issue":"5","key":"510_CR7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1532-5415.2008.01681.x","volume":"56","author":"KM Sink","year":"2008","unstructured":"Sink KM, Thomas J, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008;56(5):847\u201353.","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"510_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s12603-009-0196-5","volume":"13","author":"AT Isik","year":"2009","unstructured":"Isik AT, Celik T, Bozoglu E, Doruk H. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging. 2009;13(8):672\u20136.","journal-title":"J Nutr Health Aging."},{"issue":"8","key":"510_CR9","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/j.1532-5415.2009.02369.x","volume":"57","author":"R Sakakibara","year":"2009","unstructured":"Sakakibara R, Ogata T, Uchiyama T, et al. How to manage overactive bladder in elderly individuals with dementia? a combined use of Donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geriatri Soc. 2009;57(8):1515\u20137.","journal-title":"J Am Geriatri Soc."},{"issue":"11","key":"510_CR10","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/j.1532-5415.2011.03654.x","volume":"59","author":"DM Boudreau","year":"2011","unstructured":"Boudreau DM, Yu O, Gray SL, et al. Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. J Am Geriatr Soc. 2011;59(11):2069\u201376.","journal-title":"J Am Geriatr Soc"},{"key":"510_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s13311-016-0511-x","volume":"15","author":"TN Chase","year":"2017","unstructured":"Chase TN, Farlow MR, Clarence-Smith K. Donepezil Plus Solifenacin (CPC-201) treatment for Alzheimer\u2019s disease. Neurotherapeutics. 2017;15:405\u201316.","journal-title":"Neurotherapeutics."},{"issue":"5","key":"510_CR12","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1046\/j.1532-5415.2002.50208.x","volume":"50","author":"CM Roe","year":"2002","unstructured":"Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc. 2002;50(5):836\u201342.","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"510_CR13","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/j.1532-5415.2004.52563.x","volume":"52","author":"RM Carnahan","year":"2004","unstructured":"Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc. 2004;52(12):2082\u20137.","journal-title":"J Am Geriatr Soc"},{"key":"510_CR14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archinte.165.7.808","volume":"165","author":"SS Gill","year":"2005","unstructured":"Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165:808\u201313.","journal-title":"Arch Intern Med"},{"issue":"7","key":"510_CR15","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/j.1532-5415.2009.02258.x","volume":"57","author":"A Modi","year":"2009","unstructured":"Modi A, Weiner M, Craig BA, et al. Concomitant use of anticholinergics with acetylcholinesterase inhibitors in medicaid recipients with dementia and residing in nursing homes. J Am Geriatr Soc. 2009;57(7):1238\u201344.","journal-title":"J Am Geriatr Soc"},{"key":"510_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/pds.1739","volume":"18","author":"M Robinson","year":"2009","unstructured":"Robinson M, Rowett D, Leverton A, Mabbott V. Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors. Pharmacoepidemiol Drug Saf. 2009;18:659\u201364.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"510_CR17","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/jgs.12431","volume":"61","author":"AS Efjestad","year":"2013","unstructured":"Efjestad AS, Molden E, Oksengard AR. Pharmacist-initiated management of antagonistic interactions between anticholinergic drugs and acetyl cholinesterase inhibitors in individuals with dementia. J Am Geriatr Soc. 2013;61(9):1624\u20135.","journal-title":"J Am Geriatr Soc."},{"issue":"6","key":"510_CR18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/JCP.0000000000000218","volume":"34","author":"S Torvinen-Kiiskinen","year":"2014","unstructured":"Torvinen-Kiiskinen S, Taipale H, Tanskanen A, et al. Concomitant use of acetylcholine esterase inhibitors and urinary antispasmodics among finish community-dwelling persons with Alzheimer disease. J Clin Psychopharmacol. 2014;34(6):722\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"150","key":"510_CR19","first-page":"156","volume":"23","author":"Prescire Editorial Staff","year":"2014","unstructured":"Prescire Editorial Staff. Alzheimer\u2019s disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors. Prescrire Int. 2014;23(150):156.","journal-title":"Prescrire Int."},{"issue":"1","key":"510_CR20","first-page":"262","volume":"23","author":"A Escolano Pueyo","year":"2016","unstructured":"Escolano Pueyo A, Casajus Lagranja P, Arrieta Navarro R, et al. Concomitant use of drugs with anticholinergic effects and acetylcholinesterase inhibitors in elderly people with cognitive impairment in a nursing home. Eur J Hosp Pharm. 2016;23(1):262.","journal-title":"Eur J Hosp Pharm."},{"issue":"7","key":"510_CR21","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/jgs.14220","volume":"64","author":"P Lampela","year":"2016","unstructured":"Lampela P, Taipale H, Hartikainen S. Use of cholinesterase inhibitors increases initiation of urinary anticholinergics in persons with alzheimer\u2019s disease. Am J Geriatr Soc. 2016;64(7):1510\u20132.","journal-title":"Am J Geriatr Soc."},{"key":"510_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000454948","volume":"7","author":"AS Efjestad","year":"2017","unstructured":"Efjestad AS, Ihle-Hansen H, Hjellvik V, Salvesen H. Comedication and treatment length in users of acetylcholinesterase inhibitors. Dement Geriatr Cogn Disord Extra. 2017;7:30\u201340.","journal-title":"Dement Geriatr Cogn Disord Extra."},{"issue":"3","key":"510_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/jgs.14034","volume":"64","author":"CE Reppas-Rindlisbacher","year":"2016","unstructured":"Reppas-Rindlisbacher CE, Fischer HD, Fung K, et al. Anticholinergic drug burden in persons with dementia taking a cholinesterase inhibitor: the effect of multiple physicians. J Am Geriatr Soc. 2016;64(3):492\u2013500.","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"510_CR24","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1111\/jgs.13713","volume":"63","author":"BJ Zarowitz","year":"2015","unstructured":"Zarowitz BJ, Allen C, O\u2019Shea T, et al. Challenges in the pharmacological management of nursing home residents with overactive bladder or urinary incontinence. J Am Geriatr Soc. 2015;63(11):2298\u2013307.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"510_CR25","first-page":"343","volume":"9","author":"DB Ng","year":"2016","unstructured":"Ng DB, McCart M, Klein C, et al. Evaluating outcomes in patients with overactive bladder within an integrated healthcare delivery system using treatment patterns analyzer. Am Health Drug Benefits. 2016;9(6):343\u201353.","journal-title":"Am Health Drug Benefits."},{"issue":"2","key":"510_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/jgs.14498","volume":"65","author":"AR Green","year":"2017","unstructured":"Green AR, Segal J, Tian J, et al. Use of bladder antimuscarinics in older adults with impaired cognition. J Am Geriatri Soc. 2017;65(2):390\u20134.","journal-title":"J Am Geriatri Soc."},{"key":"510_CR27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00192-011-1411-6","volume":"22","author":"K Glavind","year":"2011","unstructured":"Glavind K, Chancellor M. Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity. Int Urogynecol J. 2011;22:907\u201317.","journal-title":"Int Urogynecol J"},{"key":"510_CR28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/ageing\/afv077","volume":"44","author":"M Oelke","year":"2015","unstructured":"Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international concensus validation process (LUTS-FORTA 2014). Age Aging. 2015;44:745\u201355.","journal-title":"Age Aging."},{"issue":"5","key":"510_CR29","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.clpt.2004.01.015","volume":"75","author":"EL Siegler","year":"2004","unstructured":"Siegler EL, Reidenberg M. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther. 2004;75(5):484\u20138.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-017-0510-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0510-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0510-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T19:33:19Z","timestamp":1547839999000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-017-0510-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1007\/s40266-017-0510-6","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"19 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Laura K. Triantafylidis, Jenna S. Clemons, John Roefaro and Kristin M. Zimmerman have no conflicts of interest that are directly relevant to the content of this article. Emily P. Peron has received a speaker\u2019s honorarium from the American Society of Consultant Pharmacists.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}